Molina, Ana M.
NewYork–Presbyterian Hospital · Weill Cornell Medicine · Weill Cornell Medical Center
5 papers on CoChatORCID 0000-0003-2025-9418
Most cited papers
- Verified
Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225 Ac-J591
Tagawa, S. T., Thomas, C., Sartor, A. O., Sun, M., Stangl-Kremser, J., Bissassar, M., Vallabhajosula, S., Castellanos, S. H., Nauseef, J. T., Sternberg, C. N., et al. (2024) · Journal of Clinical Oncology
Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research
Cited by 78
- Verified
Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
Vlachostergios, P. J., Niaz, M. J., Sun, M., Mosallaie, S. A., Thomas, C., Christos, P. J., Osborne, J. R., Molina, A. M., Nanus, D. M., Bander, N. H., et al. (2021) · Frontiers in Oncology
Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment
Cited by 43
- Verified
Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T.
Tagawa, S. T., Sun, M. P., Nauseef, J. T., Thomas, C., Huicochea Castellanos, S., Thomas, J. E., Davidson, Z., Stangl-Kremser, J., Bissassar, M., Palmer, J., et al. (2023) · Journal of Clinical Oncology
Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Diagnosis and Treatment
Cited by 11
- Verified
Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).
Tagawa, S. T., Osborne, J., Fernandez, E., Thomas, C., Niaz, M. J., Ciriaco, A., Vallabhajosula, S., Vlachostergios, P. J., Molina, A. M., Sternberg, C. N., et al. (2020) · Journal of Clinical Oncology
Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research
Cited by 10
- Verified
1406P Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)
Lang, J., Tagawa, S. T., Slovin, S., Emamekhoo, H., Rathkopf, D., Abida, W., Autio, K., Xiao, H., Molina, A. M., Eickhoff, J., et al. (2022) · Annals of Oncology
Prostate Cancer Treatment and ResearchLung Cancer Treatments and Mutations
Cited by 9
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free